Efficacy and Safety of Datopotamab Deruxtecan in Patients with Pretreated Advanced/Metastatic NSCLC with Actionable Genomic Alterations By Ogkologos - January 27, 2025 301 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the TROPION-Lung05 study Source RELATED ARTICLESMORE FROM AUTHOR AI-Supported Mammography Screening Shows Favourable Outcomes Compared with Standard Double Reading FDA Approves Daratumumab and Hyaluronidase-fihj with Bortezomib, Lenalidomide, and Dexamethasone for Patients with Newly Diagnosed Multiple Myeloma Advanced and metastatic prostate cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up MOST POPULAR College Basketball Star Plays First Game in Nearly Two Years After... December 1, 2020 Combining Enzalutamide with Radium-223 Significantly Improves rPFS as First-Line Therapy for... August 27, 2025 ACHIEVE-2 Results of Oxaliplatin-Based Adjuvant Chemotherapy in Asian Patients with High-Risk... October 27, 2020 FDA Approves Penpulimab-kcqx for Non-keratinizing Nasopharyngeal Carcinoma May 23, 2025 Load more HOT NEWS It’s a fair COP: Why our chief clinician went to a... “Selfless and Incredible” Mother Leaves Behind Five Children After Battling Breast... FDA Approves Mirvetuximab Soravtansine-gynx for FRα-positive, Platinum-resistant Epithelial Ovarian, Fallopian Tube,... ESMO 2024 Press Conference
